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Purpose: SCD is characterized by chronic organ dysfunction and
poor quality of life (QOL). Myeloablative conditioning (MAC) and
AlloSCT for SCD is the only curative therapy for children who are
at high risk for SCD related morbidity and mortality (Bhatia et al,
BMT, 2008).MAC and alloSCT are associated with significant acute
morbidity and late effects (Satwani/Cairo et al, BBMT 2005). De-
spite the emerging clinical benefit of RTC alloSCT in SCD
(Bhatia/Cairo et al, ASBMT, 2011), little is known about its impact
on the longitudinal QOL of these patients. Therefore, the objective
of this study was to serially evaluate the QOL of children who re-
ceived RTC alloSCT for SCD.
Methods: Hierarchical linear modeling was used to explore trends
in PedsQL 4.0 physical, emotional, and social functioning sub-scales
and select individual items of 14 children$ 5 years of age undergo-
ing alloSCT for SCD between 2004 and 2008 at Columbia Univer-
sity Medical Center. QOL was assessed once pre-alloSCT and days
100, 180, 365, and 730, post-alloSCT. Post hoc exploratory analyses
were performed to further evaluate the effect of RTC and alloSCT
on outcomes. Effect sizes (ES) were included to describe the magni-
tude of difference in scores from baseline.
Results:Mean age: 9.9 years. Emotional and social functioning was
stable over time. Physical functioning (PF) was estimated to im-
prove from baseline (BL) for parent (M 5 69.54) and child self-
report (M 5 72.96) at a rate of 0.57 (p 5 0.06) and 0.43 (p 5
0.16) points per month (ppm) respectively, with a large difference
estimated at 2-years post-alloSCT by parent report (ES 5 0.93
SD) and a moderate difference by child self-report (ES 5 0.70
SD). Post hoc analysis of parent reported PF items revealed statisti-
cally significant improvements from BL in running, pain, and fa-
tigue (Table 1). A large ES difference was estimated for each of
these items at 2-years post-alloSCT with running scoring 0.99 SD
higher, pain improving by 1.72 SD, and fatigue by 1.31 SD.
Children who received a matched related donor (MRD) transplant
(M 5 69.05) significantly improved at a rate of 0.93 ppm/11.31
points per year (ppy) (t 5 3.08; p 5 0.00), whereas children who
received a matched unrelated donor (MUD) alloSCT reported
a significant decline from BL (M 5 85.14) in PF of 2.57 ppm/
31.23 ppy (t 5 3.74; p 5 0.00).
Conclusion: RTC and alloSCT in poor risk SCD was associated
with significant improvements in physical functioning including run-
ning, pain and fatigue.
Table 1. Models for Physical Functioning Items by Rater
Parent ChildFixed Effect Coeff SD P Coeff SD PWalking
Intercept, b00 77.71 14.45 0.00 86.63 10.11 0.00
Time, b10 0.67 21.36 0.12 0.75 14.99 0.02
Running
Intercept, b00 71.21 21.89 0.00 70.02 27.04 0.00
Time, b10 0.91 22.28 0.05 0.50 25.07 0.34
Exercise
Intercept, b00 74.01 21.31 0.00 72.19 12.09 0.00
Time, b10 -0.27 20.29 0.52 0.25 26.95 0.64
Lifting
Intercept, b00 69.62 16.43 0.00 63.45 9.80 0.00
Time, b10 0.29 26.69 0.59 0.01 34.24 0.99
Hurt or Ache
Intercept, b00 53.47 24.03 0.00 81.07 24.78 0.00
Time, b10 1.11 15.69 0.00 0.53 24.60 0.30(Continued )Table 1. (Continued)Parent ChildFixed Effect Coeff SD P Coeff SDSPLow Energy
Intercept, b00 60.05 16.15 0.00 74.97 1.29 0.00
Time, b10 1.20 22.35 0.01 -0.29 36.01 0.67200
CHRONIC GVHD AND AGE ARE NOT ASSOCIATED WITH BONE MINERAL
DENSITY LOSS IN THE SECOND DECADE POST-ALLOGENEIC STEM CELL
TRANSPLANTATION
Pophali, P.A.1, Klotz, J.1, Koklanaris, E.1, Savani, B.N.2, Chawla, K.1,
Le, R.Q.1, Wu, C.1, Barrett, J.1, Battiwalla, M.1 1NHLBI, NIH,
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Introduction: Accelerated bone mineral density loss (BMDL) oc-
curs early after allogeneic stem cell transplantation (SCT) but little
is known about the natural history of BMDL in the second decade
(2ndD) of survivorship.
Methods:We evaluated 134 recipients (77 males and 57 females) of
allogeneic SCT performed between 1993 and 2006, who survived
.3 years. Median age at transplant was 35 years. Transplant indica-
tions wereCML (61), acute leukemia (43),MDS (18) and others (12).
Patients received$12 GyTBI-based (120) or reduced intensity con-
ditioning (14) followed by marrow (15) or T cell depleted peripheral
blood SCT (119). Post-SCT, all patients received calcium/vitaminD
supplementation but not bisphosphonates. All women received hor-
mone replacement therapy. Forty-three of 111 patients having
chronic GVHD required systemic immunosuppressive therapy for
.3 years (IST.3). A subset of 42 survivors in their 2ndD (median
age 47 years) was identified.
Survivors were classified by lowest T-scores (WHO) as normal
($-1) or BMDL: osteopenia (\-1 and .-2.5) and osteoporosis
(#-2.5, Z-score\-2 for children). Test for trends used the linear
mixed model. Multivariable linear regression was performed for
the lowest T-scores and logistic regression for osteoporosis and
BMDL.
Results: BMDL occurred in 105 (78%) survivors: 64 (48%) osteo-
penic and 41 (31%) osteoporotic. Trend analysis showed a gradual
but significant improvement in T-scores over time. The rate of im-
provement was greater in younger survivors but was unaffected by
gender. In multivariable analyses, 4th quartile age (p 5 0.001) and
IST.3 (p 5 0.047) were significantly associated with the lowest
T-score. Age in the 4th quartile (odds ratio 3.4, p\0.01) and IST
.3 (odds ratio 2.3, p 5 0.05) also increased the risk of osteoporosis.
Primary diagnosis, conditioning regimen, stem cell source and gen-
der were not statistically significant.
Thirty-one (74%) 2ndD survivors continued to have BMDL: 16
(38%) osteopenic and 15 (36%) osteoporotic. Chronic GVHD and
age had no association with T-score, osteoporosis or BMDL in
this subset.
Conclusions: There is a high prevalence of BMDL in allogeneic
SCT survivors with a gradual trend towards improvement with
time, influenced by age but not gender. Age and IST.3 are signifi-
cantly associated with BMDL in the first decade. The loss of associ-
ation with age and prolonged IST in the 2ndD survivors implies that
other factors may account for persistent BMDL in the 2ndD.201
FLUDARABINE-BASED REDUCED-INTENSITY (RIC) OR REDUCED-
TOXICITY CONDITIONING (RTC) MAY BE ASSOCIATED WITH INCREASED
RISK FOR SECONDARY MALIGNANCIES AFTER ALLOGENEIC STEM-CELL
TRANSPLANTATION (SCT)
Shimoni, A., Shem-Tov, N., Tallis, E., Danylesko, I., Volchek, Y.,
Yerushalmi, R., Nagler, A. Chaim Sheba Medical Center, Tel-Hashomer,
Israel
Secondary malignancies are a known complication in long-term
survivors following myeloablative conditioning (MAC), however277
